A 9-minute psychedelic cut depression scores by 15 points in a single-dose trial
Psychedelic and ketamine research had a genuinely strange week — one drug worked faster than almost anyone expected, and another's most-cited effects in mice turned out to be surprisingly hard to reproduce.
Here's what the evidence actually showed.
🐸 Toad Venom, 9 Minutes, and a 57% Remission Rate
- 5-MeO-DMT — the primary psychoactive compound in Sonoran Desert toad secretion — was tested as an inhaled treatment for treatment-resistant depression in a phase 2b trial. The active drug produced a 15.5-point drop in depression scores versus placebo by day 8, with 57.5% of patients in remission compared to 0% on placebo.
- The median psychoactive window lasted 9–14 minutes depending on dose, and 97.5% of patients were ready for discharge within one hour — a dramatically shorter session than psilocybin or MDMA protocols.
- The catch: nearly all the remission data comes from a single randomized trial, no protocol-mandated therapy was included, and the compound's receptor profile is genuinely unusual — it binds serotonin receptors with a roughly 30- to 300-fold preference for one subtype over the one most psychedelics target.
Why it matters: If the results replicate in larger phase 3 studies, a sub-hour, therapy-optional session model would represent a meaningfully different clinical format than anything currently approved.
Key Findings
🍄 Psilocybin's Persistent Effects in Mice Were Surprisingly Hard to Pin Down
- Five independent labs ran the same psilocybin experiment on roughly 200 mice each and found consistent acute results: more anxiety-like behavior and reduced fear expression right after dosing.
- The persistent effects — reduced anxiety and depression-like behavior 24 hours later, improved fear extinction, social reward changes — did not replicate reliably across labs, suggesting those reported effects may be modest or inconsistent in this animal model.
🧠 Psilocybin May Shift Brain Chemistry Through Astrocytes, Not Just Neurons
- A study in rodents found that psilocybin reduced inhibitory signaling in the brain's reward center by lowering GABA levels specifically inside astrocytes — the support cells of the brain — rather than in neurons directly.
- The mechanism involved changes in astrocyte gene activity linked to a GABA-metabolizing enzyme, triggered upstream by serotonin receptor signaling. This adds a non-neuronal layer to how psilocybin may work.
💊 MDMA-Assisted Therapy Tested for Social Anxiety in a Randomized Trial
- A randomized, open-label, wait-list controlled trial evaluated MDMA-assisted therapy for social anxiety disorder, building on a prior placebo-controlled study that showed promise for the same indication.
- MDMA's known effects on socio-emotional processing make it a mechanistically plausible candidate for social anxiety, though the open-label design limits how firmly conclusions can be drawn from this trial.
⚡ Combining Brain Stimulation With Ketamine May Extend Its Short Window
- Ketamine's antidepressant effects in treatment-resistant depression typically fade within days. A preliminary double-blind trial tested whether intermittent theta-burst stimulation — a form of non-invasive brain stimulation — applied after ketamine could extend that response.
- The study also examined whether any sustained benefit was associated with changes in large-scale brain network activity, though results are described as preliminary.
🌿 Syrian Rue and Ayahuasca Vine Evolved the Same Molecules Independently
- A genomics and enzyme study found that Syrian rue and the ayahuasca vine — plants separated by over 100 million years of evolution on different continents — independently evolved the same class of neuroactive compounds called harmala alkaloids, which inhibit a key enzyme involved in breaking down serotonin and related molecules.
- The convergence happened through independent duplication of an ancestral enzyme from serotonin biosynthesis, a finding the researchers describe as convergent evolution at the levels of enzymes, pathways, and genomes.
🔬 The Receptor Signal That Was Supposed to Explain Hallucinations Is Disputed
- Two papers this week clashed over whether activation of inhibitory G proteins — a specific molecular signaling pathway — reliably distinguishes hallucinogenic from non-hallucinogenic serotonin receptor agonists.
- One study using human post-mortem brain tissue found that hallucinogens activated both a canonical and an inhibitory protein pathway, while non-hallucinogens activated only the canonical one. A separate paper reanalyzed the original source data behind this claim and argued the inhibitory pathway is less predictive than the canonical signals.
Implications
The week's sharpest tension sits between clinical speed and mechanistic clarity. A 9-minute treatment is showing remission rates that demand attention, while the basic science — what psilocybin actually does in the brain, which receptor signals produce hallucinations, whether mouse models predict human outcomes — remains actively contested among researchers.
Studies in this issue
Primary sources used for this newsletter.
- The clinical drug effects of 5-MeO-DMT from toad venom in hard-to-treat depressionmain storyCNS drugs2026-11-04PMID 42983054
- Psilocybin's effects on mouse behavior across multiple research centerskey findingNature neuroscience2026-11-02PMID 42972049
- MDMA-assisted therapy for social anxiety disorder tested in a randomized trial with a wait-list controlkey findingJournal of affective disorders2026-11-06PMID 42994762
- Psilocybin changes reward system activity by affecting support cell gene activitykey findingExperimental & molecular medicine2026-11-05PMID 42988866
- Activation of a specific signaling pathway in the thinking areas of the brain distinguishes hallucinogenic from non-hallucinogenic serotonin 5-HT2A receptor activatorskey findingNeurochemistry international2026-11-06PMID 42994673
- Harmala Alkaloids Evolved Separately in Syrian Rue and Ayahuasca Plantskey findingbioRxiv : the preprint server for biology2026-11-06PMID 42990209
- Using brief brain stimulation to prolong early ketamine effects in hard-to-treat depression: A preliminary controlled trialkey findingPsychiatry and clinical neurosciences2026-11-05PMID 42983941
Continue reading
All Psychedelic Science issuesGet the next Psychedelic Science issue
Seven papers, once a week. Free.